SMARCB1-Deficient Sinonasal Carcinoma: Systematic Review and Case Report

Parsel, Sean M.; Jawad, Basit; McCoul, Edward D.

doi:10.1016/j.wneu.2020.01.130

Cited by 19 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the remaining 192 patients, 72 patients whose individual baseline patient characteristics, treatment details, and survival outcomes could not be identified and verified [2,16,19,20,23,[28][29][30]34,35,38], and they were thus not included into our survival analysis. As a result, only 120 patients with data availability of baseline patient characteristics, disease stage, and survival outcomes in 25 publications were included for survival and prognostic factor analyses [1,2,11,[13][14][15][16][17]19,[21][22][23][24][25][26][27][31][32][33]36,37,[39][40][41][42].…”

Section: Search Strategy Resultsmentioning

confidence: 99%

“…Here, we have presented the largest systematic review of patient characteristics, treatment details, and survival outcomes of patients with SMARCB1-deficient sinonasal carcinoma, among the two previously published which did not include all reported cases [29,42]. SMARCB-1 deficient sinonasal carcinoma, first reported in 2014, remains one of the rarest and most poorly understood sinonasal malignancies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes

Lee

Tsang

et al. 2022

Cancers

View full text Add to dashboard Cite

(1) Background: SMARCB1 (INI-1)-deficient sinonasal carcinoma is a rare sinonasal malignancy; since its discovery and description in 2014, less than 200 cases have been identified. It is almost impossible to perform randomized-controlled trials on novel therapy to improve treatment outcomes in view of its rarity. We performed a systematic review of all the published case reports/series and included our patients for survival analysis. (2) Methods: In this systematic review, we searched from PubMed-MEDLINE, EMBASE, Scopus, Cochrane Library, CINAHL, and Google Scholar for individual patient data to identify and retrieve all reported SMARCB1-deficient sinonasal carcinoma. Clarification on treatment details and the most updated survival outcomes from all authors of the published case reports/series were attempted. Survival analysis for overall survival (OS) and identification of OS prognostic factors were performed. This systematic review was registered with PROSPERO (CRD42022306671). (3) Results: A total of 67 publications were identified from the systematic review and literature search. After excluding other ineligible and duplicated publications, 192 patients reported were considered appropriate for further review. After excluding duplicates and patients with incomplete pretreatment details and survival outcomes, 120 patients were identified to have a complete set of data including baseline demographics, treatment details, and survival outcomes. Together with 8 patients treated in our institution, 128 patients were included into survival analysis. After a median follow up of 17.5 months (range 0.3–149.0), 50 (46.3%) patients died. The 1-year, 2-year and 3-year OS rates were 84.3% (95% CI % 77.6–91.0), 62.9% (95% CI 53.1–72.7), and 51.8% (95% CI 40.8–62.8), respectively, and the median OS was 39.0 months (95% CI 28.5–49.5). Males (p = 0.029) and T4b disease (p = 0.013) were significant OS prognostic factors in univariable analysis, while only T4b disease (p = 0.017) remained significant in multivariable analysis. (4) Conclusions: SMARCB1-deficient sinonasal carcinoma is an extremely aggressive sinonasal malignancy with a dismal prognosis. Early diagnosis and a multimodality treatment strategy are essential for a better treatment and survival outcome.

show abstract

Section: Search Strategy Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes

Lee

Tsang

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Nasal cavity and paranasal sinus cancer accounts for about 3%-5% of the entire head and neck tumors, and SDSC is even rarer. The latest literature reports about 82 cases of this disease in the world [3], The disease was reported for the first time in my country in 2018, and currently there are only 2 reports in Chinese search [4,5]. In 2019, Goda et al [6] reported the disease for the first time in Japan.…”

Section: Discussionmentioning

confidence: 99%

SMARCB1-Deficient Sinonasal Carcinoma: A Case Report and Review of the Literature

Mb¹,

Jj²,

Rk³

et al. 2020

COO

View full text Add to dashboard Cite

“…O carcinoma sinosal SMARCB1-deficiente representa um subtipo de carcinoma sinosal pouco diferenciado/indiferenciado raro, recentemente descoberto, de elevada agressividade e propensão à metástase, dispondo de apenas 89 casos descritos na literatura, atingindo pacientes de 19 a 89 anos, com leve predileção por homens [1][2][3][4] . Este tumor é resultante da inativação do gene SMARCB1, visualizada em exames imunohistoquímicos pela perda completa da expressão de SMARCB1 (INI1), proteína envolvida no remodelamento de cromatina e regulação transcripcional, conhecida pela sua atividade de supressão tumoral 2,3 .…”

Section: Introductionunclassified

Reabilitação com Prótese Obturadora Maxilar após Exérese de Carcinoma Sinosal INI1-(SMARCB1)-Deficiente

et al. 2022

View full text Add to dashboard Cite

Ressecções cirúrgicas para tratamento de carcinomas sinosais provocam alterações severas na aparência, interferindo na autoestima dos pacientes e induzindo-os ao isolamento social. A reabilitação com próteses bucomaxilofaciais é a modalidade de tratamento preferível em casos de tumores com altas taxas de recidiva em que a correção cirúrgica é contraindicada, pois melhora a estética e atenua as dificuldades de mastigação, deglutição e fonação. Este artigo objetiva relatar um caso de reabilitação utilizando prótese obturadora maxilar em paciente submetido à maxilectomia parcial que originou comunicação bucosinusal. Paciente do gênero masculino, 32 anos, procurou atendimento odontológico após exérese de um carcinoma sinosal raro. Após anamnese, exames intra e extraoral e análise radiográficas, foi planejada a confecção de prótese parcial removível superior com obturador palatino. Após moldagem da arcada superior, foi obtido o modelo de estudo que foi levado ao delineador, e foi planejada a armação metálica da prótese parcial removível. Foram executados os nichos e desgastes compensatórios e em seguida a moldagem de trabalho, originando o modelo de trabalho sobre o qual foi confeccionada a armação metálica. Após prova da armação metálica e registro oclusal, os modelos foram montados no articulador semiajustável, os dentes foram selecionados e montados. Na prova estética e funcional dos dentes foi constatado o restabelecimento estético e fonético do paciente. Em seguida, foram realizadas moldagem com boca fechada, acrilização, instalação e proservações da prótese. Conclui-se que a prótese obturadora palatina veda a comunicação bucosinusal e promove melhorias na estética, fonética e mastigação, restabelecendo autoconfiança e ressocialização do paciente.

show abstract

SMARCB1-Deficient Sinonasal Carcinoma: Systematic Review and Case Report

Cited by 19 publications

References 20 publications

SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes

SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes

SMARCB1-Deficient Sinonasal Carcinoma: A Case Report and Review of the Literature

Reabilitação com Prótese Obturadora Maxilar após Exérese de Carcinoma Sinosal INI1-(SMARCB1)-Deficiente

Contact Info

Product

Resources

About